KAS
RXRX icon

Kemnay Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Kemnay Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-121,573
Closed -$2.08M – 38
2021
Q4 		$2.08M Buy
+121,573
New +$2.29M 0.29% 34

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kemnay Advisory Services's RXRX Position: Q1 2022 in Review

Kemnay Advisory Services sold out of Recursion Pharmaceuticals (RXRX) in Q1 2022, closing a stake of 121,573 shares — an estimated $2.08M sold.

Kemnay Advisory Services first reported a position in RXRX in Q4 2021 and held it in 1 quarter. The position peaked at $2.08M in Q4 2021. 128 funds tracked by Wall St. Rank hold RXRX as of Q1 2022.

  • Kemnay Advisory Services reported no remaining Recursion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Kemnay Advisory Services sold 121,573 Recursion Pharmaceuticals shares in Q1 2022, an estimated $2.08M.
  • Kemnay Advisory Services first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Kemnay Advisory Services's Recursion Pharmaceuticals position peaked at $2.08M in Q4 2021.
  • 128 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2022.

Based on Kemnay Advisory Services's 13F filing for Q1 2022, filed 16 May 2022.